BioCentury | Jan 1, 2007
Clinical News

PH80: Phase II data

...significantly higher for the PH80 group vs. placebo patients during the month following treatment (p<0.01). Pherin Pharmaceuticals Inc....
BioCentury | Jul 16, 2001
Company News

DoubleTwist deal

...Laboratories Fournier; M.D. Anderson Cancer Center; the National Cancer Institute; N.V. Organon; Oxagen Ltd. ; Pherin Pharmaceuticals Inc....
BioCentury | Feb 5, 2001
Clinical News

Vomeropherin: Began Phase I testing

Pherin Pharmaceuticals Inc., Mountain View, Calif. Product: Vomeropherin Business: Neurological Therapeutic category: Neurotransmission Target: Chemoreceptors on the vomeronasal organ Description: Chemoreceptor stimulator that modulates the hypothalamus Indication: Treat female anxiety disorders End point: Safety Status:...
BioCentury | Sep 11, 2000
Company News

Pherin, Taisho deal

...pay Pherin license and milestone fees for vomeropherin compounds. Pherin also is eligible for royalties. Pherin Pharmaceuticals Inc....
BioCentury | Nov 22, 1999
Company News

Pherin scientific advisory board update

Pherin Pharmaceuticals Inc. , Menlo Park, Calif. Business: Neurological Appointed: George Rosenkranz, formerly president and CEO of Syntex Corp.; Elias Corey, professor of chemistry at Harvard University WIR Staff...
BioCentury | Jul 12, 1999
Company News

Pherin, Janssen Pharmaceutica N.V. deal

...agreement, Johnson & Johnson Development Corp. purchased $1.5 million worth of Pherin convertible preferred stock. Pherin Pharmaceuticals Inc....
BioCentury | Oct 19, 1998
Clinical News

PH80 nasally administered vomeropherin compound: Phase I

Pherin Pharmaceuticals Inc. , Menlo Park, Calif. Product: PH80 nasally administered vomeropherin compound Indication: Treat premenstrual syndrome (PMS) Status: Pherin and partner N.V. Organon will begin on Nov. 1 Phase I single and multiple dose escalation...
BioCentury | Jul 28, 1997
Company News

Pherin, N.V. Organon deal

...work in both indications. Organon is a subsidiary of Akzo Nobel N.V. (Armhem, the Netherlands). Pherin Pharmaceuticals Inc....
Items per page:
1 - 8 of 8
BioCentury | Jan 1, 2007
Clinical News

PH80: Phase II data

...significantly higher for the PH80 group vs. placebo patients during the month following treatment (p<0.01). Pherin Pharmaceuticals Inc....
BioCentury | Jul 16, 2001
Company News

DoubleTwist deal

...Laboratories Fournier; M.D. Anderson Cancer Center; the National Cancer Institute; N.V. Organon; Oxagen Ltd. ; Pherin Pharmaceuticals Inc....
BioCentury | Feb 5, 2001
Clinical News

Vomeropherin: Began Phase I testing

Pherin Pharmaceuticals Inc., Mountain View, Calif. Product: Vomeropherin Business: Neurological Therapeutic category: Neurotransmission Target: Chemoreceptors on the vomeronasal organ Description: Chemoreceptor stimulator that modulates the hypothalamus Indication: Treat female anxiety disorders End point: Safety Status:...
BioCentury | Sep 11, 2000
Company News

Pherin, Taisho deal

...pay Pherin license and milestone fees for vomeropherin compounds. Pherin also is eligible for royalties. Pherin Pharmaceuticals Inc....
BioCentury | Nov 22, 1999
Company News

Pherin scientific advisory board update

Pherin Pharmaceuticals Inc. , Menlo Park, Calif. Business: Neurological Appointed: George Rosenkranz, formerly president and CEO of Syntex Corp.; Elias Corey, professor of chemistry at Harvard University WIR Staff...
BioCentury | Jul 12, 1999
Company News

Pherin, Janssen Pharmaceutica N.V. deal

...agreement, Johnson & Johnson Development Corp. purchased $1.5 million worth of Pherin convertible preferred stock. Pherin Pharmaceuticals Inc....
BioCentury | Oct 19, 1998
Clinical News

PH80 nasally administered vomeropherin compound: Phase I

Pherin Pharmaceuticals Inc. , Menlo Park, Calif. Product: PH80 nasally administered vomeropherin compound Indication: Treat premenstrual syndrome (PMS) Status: Pherin and partner N.V. Organon will begin on Nov. 1 Phase I single and multiple dose escalation...
BioCentury | Jul 28, 1997
Company News

Pherin, N.V. Organon deal

...work in both indications. Organon is a subsidiary of Akzo Nobel N.V. (Armhem, the Netherlands). Pherin Pharmaceuticals Inc....
Items per page:
1 - 8 of 8